Lexaria Bioscience (LEXX) Invested Capital (2011 - 2022)
Lexaria Bioscience (LEXX) posted Invested Capital of $7906.0 for Q2 2022, little changed sequentially from $7926.0 in Q3 2021, and up 5.32% YoY from $7507.0 in Q2 2021.
Lexaria Bioscience (LEXX) Invested Capital (2011 - 2022) Analysis & Trends
Lexaria Bioscience has reported Invested Capital for 12 years, with the latest figure at $7906.0 in Q2 2022.
- Quarterly Invested Capital rose 5.32% year-over-year to $7906.0 in Q2 2022, while the trailing twelve-month figure through Feb 2023 was $7906.0 (down 48.77% YoY) and the FY2021 annual result came in at $7926.0, down 86.5% from the prior year.
- Invested Capital was little changed at $7906.0 in Q2 2022 per LEXX's latest filing, from $7926.0 in the prior quarter.
- Over five years, Invested Capital peaked at $87185.0 in Q4 2020 and troughed at $1600.0 in Q1 2020.
- A 5-year average of $22753.4 and a median of $8518.0 in 2018 frame the typical range for Invested Capital.
- The sharpest annual moves came in 2018 and 2019: Invested Capital slumped 98.02% in 2018, then jumped 512.3% in 2019.
- Over 5 years, Invested Capital stood at $21654.0 in 2018, then soared by 71.79% to $37200.0 in 2019, then surged by 134.37% to $87185.0 in 2020, then plunged by 90.91% to $7926.0 in 2021, then retreated by 0.25% to $7906.0 in 2022.
- According to Business Quant data, Invested Capital over the past three periods registered $7906.0, $7926.0, and $7507.0 for Q2 2022, Q3 2021, and Q2 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 7,906.00 |
| Aug 31, 2021 | 7,926.00 |
| May 31, 2021 | 7,507.00 |
| Feb 28, 2021 | 7,507.00 |
| Nov 30, 2020 | 87,185.00 |
| Aug 31, 2020 | 58,704.00 |
| May 31, 2020 | 29,595.00 |
| Feb 29, 2020 | 1,600.00 |
| Nov 30, 2019 | 37,200.00 |
| Aug 31, 2019 | 48,096.00 |
| May 31, 2019 | 20,995.00 |
| Feb 28, 2019 | 5,621.00 |
| Nov 30, 2018 | 21,654.00 |
| Aug 31, 2018 | 7,855.00 |
| May 31, 2018 | 9,110.00 |
| Feb 28, 2018 | 5,594.00 |
| Nov 30, 2017 | 25,018.00 |
| Aug 31, 2017 | 42,690.00 |
| May 31, 2017 | 7,446.00 |
| Feb 28, 2017 | 282,615.00 |